The concomitant presence of other mutations, such as those involving the DNMT3A or TET2 genes, known for their association with myelodysplastic syndromes or expanded hematopoietic clones, has been found in up to 24% of VEXAS cases (Georgin-Lavialle et al., 2022). This evidence concerns the gene DNMT3A and myelodysplastic syndrome.